@entity56 is an increasing problem worldwide. @entity2023 , an inflammatory response to an allergen, affects an estimated 20-40 million @entity1 in the US, while @entity14687 is a dermatoallergic condition that affects 0.1-3% of @entity1 in the US and Europe. The primary goals of treatment for @entity2023 are to reduce symptoms, which include sneezing, rhinorrhoea and nasal congestion, improve quality of life and prevent the sequelae associated with this disease, while the goal for @entity14687 is the rapid and prolonged control of symptoms. Quantitatively, @entity112 is the most abundant mediator present during an @entity56 episode - thus, antihistamines (historically called @entity112 H(1) receptor antagonists, now called H(1) receptor inverse agonists) are a first-line defense against @entity2023 and @entity14687 . Although first-generation antihistamines can cause sedation and @entity73 , second-generation antihistamines are relatively non-sedating and free of such adverse events owing to their comparative inability to penetrate the blood-brain barrier. @entity14295 is one such second-generation antihistamine and is indicated for the treatment of @entity56 , @entity2023 and @entity14687 . It has proven efficacy against the symptoms associated with seasonal and @entity9590 , including nasal congestion, and @entity14687 . As a result, it has been shown to improve @entity1 ' quality of life. The safety and efficacy profiles of @entity14295 are well established, and published postmarketing analyses have assessed >54 000 @entity1 . Although earlier second-generation antihistamines have been associated with cardiovascular adverse effects, @entity14295 has been shown to be safe and well tolerated at nine times the recommended dose. In addition, it has been shown to not interact with concomitantly administered drugs and food. Overall, current data indicate that @entity14295 is a safe and effective treatment for @entity56 .

The safety and efficacy of XXXX for the management of @entity56 .

@entity1 :: ('9606', 'Species') :: ['patients', 'people'] @entity2023 :: ('MESH:D006255', 'Disease') :: ['Allergic rhinitis', 'including allergic rhinitis', 'allergic rhinitis'] @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive impairment'] @entity14687 :: ('MESH:D007566', 'Disease') :: ['chronic idiopathic urticaria'] @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic diseases', 'allergic', 'Allergic disease'] @entity112 :: ('MESH:D006632', 'Chemical') :: ['histamine'] @entity9590 :: ('MESH:D012221', 'Disease') :: ['perennial allergic rhinitis'] @entity14295 :: ('MESH:C121345', 'Chemical') :: ['Desloratadine', 'desloratadine']
@entity14295 :: (MESH:C121345,Chemical) :: ['desloratadine']
